Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial

Published:2022-04 Issue:4 Volume:23 Page:465-478
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kristeleit Rebecca,Lisyanskaya Alla,Fedenko Alexander,Dvorkin Mikhail,de Melo Andreia Cristina,Shparyk Yaroslav,Rakhmatullina Irina,Bondarenko Igor,Colombo Nicoletta,Svintsitskiy Valentyn,Biela Luciano,Nechaeva Marina,Lorusso Domenica,Scambia Giovanni,Cibula David,Póka Róbert,Oaknin Ana,Safra Tamar,Mackowiak-Matejczyk Beata,Ma Ling,Thomas Daleen,Lin Kevin K,McLachlan Karen,Goble Sandra,Oza Amit M

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors;Wahlberg;Nat Biotechnol,2012

2. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial;Thomas;Mol Cancer Ther,2007

3. DNA repair pathways as targets for cancer therapy;Helleday;Nat Rev Cancer,2008

4. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov,2015

5. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer;Christie;J Clin Oncol,2017

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers;Cancers;2024-09-05

2. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis;Taiwanese Journal of Obstetrics and Gynecology;2024-09

3. Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer;ESMO Open;2024-09

4. Neurological toxicities with poly (ADP-ribose) polymerase inhibitors in cancer patients: a systematic review and meta-analysis;Journal of Chemotherapy;2024-08-23

5. Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer;Journal of Translational Medicine;2024-08-21